Accelerating Medical Treatments for Serious Mental Illness
In Simple Terms
This order tells federal agencies to speed up testing, review, and possible approval of psychedelic drugs to treat serious mental illness, especially for people not helped by usual care. It also puts federal money into this work and makes it easier for some patients, including veterans, to get these drugs sooner.
Summary
President Donald J. Trump’s order directs federal agencies to speed up research, review, and possible approval of psychedelic-based treatments for serious mental illnesses, especially for patients who do not improve with standard care. It tells the FDA to prioritize certain psychedelic drugs that have already received Breakthrough Therapy status, and it orders the FDA and DEA to create a pathway for eligible patients to access these drugs under the federal Right to Try law. The order also requires the Department of Health and Human Services to devote at least $50 million in existing funds to work with states developing these treatments, and it instructs HHS, FDA, and the Department of Veterans Affairs to expand clinical trials and share data to support evaluation of these drugs. Trump says the action was issued to address high rates of suicide, serious mental illness, and veteran suffering by accelerating potential new treatment options beyond traditional medications.
Official Record
Awaiting Federal RegisterPending Federal Register publication
Analysis & Impact
💡 How This May Affect You
- Working families may see faster access to new mental health treatments, but availability and insurance coverage could vary.
- Small business owners could benefit if workers miss fewer days, though treatment rules and workplace policies may need updates.
- Students and recent graduates may gain more treatment options for severe depression, but access may depend on local providers.
- Retirees and seniors, especially veterans, may see new care options, though safety monitoring will matter for older patients.
- Urban areas may get treatments sooner; suburban and rural regions could face provider shortages and longer travel.
🏢 Key Stakeholders
- Patients with treatment-resistant mental illness and veterans may gain faster access.
- Psychedelic drug developers, clinical researchers, and specialized providers benefit from accelerated approvals.
- FDA, DEA, HHS, ARPA-H, and VA face major implementation and coordination burdens.
- Traditional psychiatric providers, cautious regulators, and insurers may face safety and coverage challenges.
- Veteran, mental health, and psychedelic-advocacy groups gain influence shaping access and safeguards.
📈 What to Expect
- FDA and DEA issue guidance on priority vouchers and Right to Try procedures.
- HHS redirects at least $50 million toward state partnerships and psychedelic research support.
- VA, HHS, and FDA begin data-sharing agreements and expand eligible clinical trial recruitment.
- More late-stage psychedelic trials enroll veterans and treatment-resistant patients across participating states.
- One or more products could reach FDA decisions, with product-specific rescheduling reviews starting.
- Access expands unevenly, constrained by provider training, state laws, and insurer reimbursement.
📚 Historical Context
- Nixon’s 1970 CSA entrenched Schedule I barriers; this order partially reverses that framework for psychedelics.
- Trump’s 2018 Right to Try law is expanded here, applying it to Schedule I psychiatric treatments.
- Biden’s 2022 mental-health initiatives emphasized conventional care; this modifies priorities toward experimental psychedelic therapeutics.
- Reagan and Bush backed faster drug approvals; using priority vouchers for psychedelics is historically novel.
- No prior president so directly linked VA, FDA, DEA, and states around psychedelic mental-health access.
News Coverage
Trump Loosens Restrictions on Psychedelic Drugs - The New York Times
Trump Loosens Restrictions on Psychedelic Drugs The New York Times
Trump signs order to accelerate access to psychedelic drug treatments - Reuters
Trump signs order to accelerate access to psychedelic drug treatments Reuters
Joe Rogan joins Trump to sign order allowing psychedelic drug research - The Hill
Joe Rogan joins Trump to sign order allowing psychedelic drug research The Hill
Trump announces reforms to accelerate access to psychedelic drug treatments - The Guardian
Trump announces reforms to accelerate access to psychedelic drug treatments The Guardian
Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugs - Fox News
Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugs Fox News
Perspective | Suicide is on the rise. Depression therapy is limited. Let’s try psychedelics. - The Washington Post
Perspective | Suicide is on the rise. Depression therapy is limited. Let’s try psychedelics. The Washington Post
Related Actions
Apr 09, 2026
FRContinuing the Suspension of Duty-Free De Minimis Treatment for All Countries
Apr 03, 2026
FRUrgent National Action to Save College Sports
Mar 31, 2026
FR